Generation Bio Investor Relations Material
Latest events
Study Result
Generation Bio
Q1 2025
7 May, 2025
Q4 2024
13 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Generation Bio Co
Access all reports
Generation Bio Co. is a biotechnology company focused on the development of genetic medicines to treat both rare and prevalent diseases. Leveraging its proprietary platform, the company is working on a range of therapies aimed at addressing conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the Nasdaq.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
GBIO
Country
🇺🇸 United States